Aggeletopoulou I, Pantzios S, Triantos C (2025) Personalized immunity: neoantigen-based vaccines revolutionizing hepatocellular carcinoma treatment. Cancers (Basel) 17:376.
Ahmad S, Bano N, Khanna K et al (2024) Reporting multitargeted potency of Tiaprofenic acid against lung cancer: molecular fingerprinting, MD simulation, and MTT-based cell viability assay studies. Int J Biol Macromol 276:133872.
Al Musaimi O, AlShaer D, de la Torre BG, Albericio F (2025) 2024 FDA TIDES (peptides and oligonucleotides) harvest. Pharmaceuticals 18:291.
Al-Sahlawi F, Yaseen Mahmood Alabdali A, Chinnappan S et al (2024) Polymer-based nanoparticles in targeted cancer therapy: a review. J Appl Pharm Sci.
Albertini B, Mathieu V, Iraci N et al (2019) Tumor targeting by Peptide-Decorated gold nanoparticles. Mol Pharm 16:2430–2444.
Alonezi S, Tusiimire J, Wallace J et al (2017) Metabolomic profiling of the synergistic effects of melittin in combination with cisplatin on ovarian cancer cells. Metabolites 7:14.
Amin M, Badiee A, Jaafari MR (2013) Improvement of pharmacokinetic and antitumor activity of pegylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm 458:324–333.
Annett S, Moore G, Short A et al (2020) FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. Br J Cancer 122:361–371.
Armstrong GR, Khot MI, Portal C et al (2022) A novel fluorescent c-met targeted imaging agent for intra-operative colonic tumour mapping: translation from the laboratory into a clinical trial. Surg Oncol 40:101679.
Banerji U, Spencer-Briggs DJ, Leslie SA (2023) Phase I/IIa trial of BT1718 in patients with advanced solid tumours.
Baun C, Naghavi-Behzad M, Hildebrandt MG et al (2024) Gastrin-releasing peptide receptor as a theranostic target in breast cancer: a systematic scoping review. Semin Nucl Med 54:256–269.
Beheshti M, Taimen P, Kemppainen J et al (2023) Value of 68Ga-labeled Bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I/II study. Eur Radiol 33:472–482.
Binkowski TA, Marino SR, Joachimiak A (2012) Predicting HLA class I non-permissive amino acid residues substitutions. PLoS One 7:e41710.
Bockorny B, Semenisty V, Macarulla T et al (2020) BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Nat Med 26:878–885.
Boohaker J, Lee RW, Vishnubhotla M P, et al (2012) The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 19:3794–3804.
Braun DA, Moranzoni G, Chea V et al (2025) A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature 639:474–482.
Brown NF, Marshall JF (2019) Integrin-mediated TGFβ activation modulates the tumour microenvironment. Cancers (Basel) 11:1221.
Brown AB, Krug LM, Maslak P et al (2008) Pilot trial of a Wilms tumor-1 (WT1) peptide vaccine in patients with thoracic and myeloid neoplasms. J Clin Oncol 26(15_suppl):3051–3051.
